Investigating the effect of zinc supplementation on probability of relapse and mental health in patients with opioid use disorder undergoing methadone maintenance treatment
Open Access
- 6 January 2023
- journal article
- research article
- Published by Springer Nature in Substance Abuse Treatment, Prevention, and Policy
- Vol. 18 (1) , 1-8
Abstract
Background: Considering different factors, such as high withdrawal rates in methadone maintenance treatment (MMT) programs alongside mental health (MH) problems appearing in patients with opioid use disorder and the lack of prior research on the effect of zinc supplementation in this respect, the present study aimed to investigate the effect of zinc supplementation on the probability of relapse (PoR) and MH problems in patients with opioid use disorder undergoing MMT. Methods: For this purpose, a randomized controlled trial with a clinical basis was fulfilled on a total of 68 patients with opioid use disorder receiving MMT, allocated to two groups, viz. intervention, and control (each one consisting of 34 individuals). Then, the participants in the intervention group were given zinc supplements combined with methadone for three months, and the controls only took methadone, according to the treatment plan. The data were collected using the Relapse Prediction Scale (RPS) and the Depression, Anxiety, and Stress Scale 21 (DASS-21) before, one month after, and at the end of the intervention program. Findings: Compared to the control group, the likelihood of drug use (p = 0.01), drug craving (p = 0.002), and the RPS total score (p = 0.002) in the intervention group was significantly lower. Moreover, the results revealed a significant decreasing trend in depression (p = 0.01), anxiety (p < 0.001), stress (p = 0.001), and the DASS-21 total score (p = 0.001) in the intervention. Compared to the control group, the DASS-21 total score (p < 0.001) in the intervention group was significantly lower. Conclusion: Accordingly, it was concluded that zinc supplementation could reduce the PoR and improve MH problems in patients with opioid use disorder experiencing MMT. However, further research is recommended to fill the gaps. Trial registration: The research protocol has also been listed on the Iranian Registry of Clinical Trials (IRCT) with code no. IRCT2020050904736N1.Keywords
All Related Versions
This publication has 35 references indexed in Scilit:
- The Italian version of the Depression Anxiety Stress Scales-21: Factor structure and psychometric properties on community and clinical samplesComprehensive Psychiatry, 2015
- Essential elements in depression and anxiety. Part IIPharmacological Reports, 2015
- Behavioral impairments in animal models for zinc deficiencyFrontiers in Behavioral Neuroscience, 2015
- Discovery of Human Zinc Deficiency: Its Impact on Human Health and DiseaseAdvances in Nutrition, 2013
- The impact of opioid analgesics on the gastrointestinal tract function and the current management possibilities [Polish version: Wpływ opioidowych środków przeciwbólowych na czynność układu pokarmowego oraz aktualne możliwości postępowania terapeutycznego p. 132]Contemporary Oncology, 2012
- Modulation of Neuronal Signal Transduction and Memory Formation by Synaptic ZincFrontiers in Behavioral Neuroscience, 2011
- HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverageThe Lancet, 2010
- A prospective evaluation of the directionality of the depression–inflammation relationshipBrain, Behavior, and Immunity, 2009
- The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety InventoriesBehaviour Research and Therapy, 1995
- Modulation of mu, delta and kappa opioid receptors in rat brain by metal ions and histidineNeuropharmacology, 1990